Stock Market News
Shire's valuation is irrational, SocGen analysts say
Shire's valuation makes no sense and investors should buy shares in the UK pharmaceuticals company, according to analysts at Societe Generale.
Shire's shares have fallen by more than 10% in 2018. The SocGen analysts said the decline was "irrational" despite an unhelpful delay to the conclusion of a review of Shire's ADHD business to the second half of 2018.
The analysts said Shire "is an outlier on consensus estimates" because of concerns its haemophilia and severe facial swelling businesses are not sustainable and that the company cannot service its debts without its ADHD division.
"We strongly disagree," the analysts, led by Justin Smith, said in a note to investors. They urged clients to emulate Berkshire Hathaway's Charlie Munger "by trying to be consistently not stupid instead of trying to be very intelligent".
Market values suggest Shire's haemophilia business is worth £20 a share and the ADHD division is worth £10 a share. That leaves the rest of Shire's businesses trading at a price to equity ratio of three times and "this is simply unjustifiable", the analysts said.
The analysts reiterated their 'buy' recommendation and target price of £8. Shire shares rose 1% to £3.47.
Shire's shares have fallen by more than 10% in 2018. The SocGen analysts said the decline was "irrational" despite an unhelpful delay to the conclusion of a review of Shire's ADHD business to the second half of 2018.
The analysts said Shire "is an outlier on consensus estimates" because of concerns its haemophilia and severe facial swelling businesses are not sustainable and that the company cannot service its debts without its ADHD division.
"We strongly disagree," the analysts, led by Justin Smith, said in a note to investors. They urged clients to emulate Berkshire Hathaway's Charlie Munger "by trying to be consistently not stupid instead of trying to be very intelligent".
Market values suggest Shire's haemophilia business is worth £20 a share and the ADHD division is worth £10 a share. That leaves the rest of Shire's businesses trading at a price to equity ratio of three times and "this is simply unjustifiable", the analysts said.
The analysts reiterated their 'buy' recommendation and target price of £8. Shire shares rose 1% to £3.47.
Related share prices |
---|
Shire Plc (SHP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price